Relationships of hHpr1/p84/Thoc1 expression to clinicopathologic characteristics and prognosis in non-small cell lung cancer

Annals of Clinical and Laboratory Science

Volumn 38, Issue 2, 2008, Pages 105-112

  Yang, Jun ^a   Li, Yanping ^a   Khoury, Thaer ^a   Alrawi, Sadir ^a   Goodrich, David W ^a   Tan, Dongfeng ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

hHpr1 p84 Thoc1; Non small cell lung cancer; Nuclear matrix proteins; Tissue microarray

Indexed keywords

HHPR1 PROTEIN; NUCLEAR MATRIX PROTEIN; PROTEIN P84; THOC1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FAMILY HISTORY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE DIFFERENCE; RNA SPLICING; SEX RATIO; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TUMOR VOLUME; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 43449092197     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Brunagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res 2002;62:2437-2442.
2. Dey P. Chromatin pattern alteration in malignant cells: an enigma. Diagn Cytopathol 2005;32:25-30.
3. Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nat Rev Cancer 2004;4:677-687.
4. Nickerson J. Experimental observations of a nuclear matrix. J Cell Sci 2001;114:463-474.
5. Ruh MF, Dunn R 2nd, Ruh TS. Interrelationships between nuclear structure and ligand-activated intracellular receptors. Crit Rev Eukaryot Gene Expr 1996;6:271-283.
6. Martelli AM, Bareggi R, Bortul R, Grill V, Narducci P, Zweyer M. The nuclear matrix andapoptosis. Histochem Cell Biol 1997;108:1-10.
7. Leman ES, Getzenberg RH. Nuclear matrix proteins as biomarkers in prostate cancer. J Cell Biochem 2002;86:213-223.
8. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996;56:1690-1694.
9. Konety BR, Nangia AK, Nguyen TS, Veitmeier BN, Dhir R, Acierno JS, et al. Identification of nuclear matrix protein alterations associated with renal cell carcinoma. J Urol 1998;159:1359-1363.
10. Getzenberg RH, Pienta KJ, Huang EY, Coffey DS. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 1991;51:6514-6520.
11. Luftner D, Possinger K. Nuclear matrix proteins as biomarkers for breast cancer. Expert Rev Mol Diagn 2002;2:23-31.
12. Partin AW, Briggman JV, Subong EN, Szaro R, Oreper A, Wiesbrock S, et al. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins. Urology 1997;50:800-808.
13. Durfee T, Mancini MA, Jones D, Elledge SJ, Lee WH. The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that colocalizes to centers for RNA processing. J Cell Biol 1994;127:609-622.
14. Gasparri F, Sola F, Locatelli G, Muzio M. The death domain protein p84N5, but not the short isoform p84N5s, is cell cycle-regulated and shuttles between the nucleus and the cytoplasm. FEBS Lett 2004;574:13-19.
15. Doostzadeh-Cizeron J, Evans R, Yin S, Goodrich DW. Apoptosis induced by the nuclear death domain protein p84N5 is inhibited by association with Rb protein. Mol Biol Cell 1999;10:3251-3261.
16. Doostzadeh-Cizeron J, Terry NH, Goodrich DW. The nuclear death domain protein p84N5 activates a G2/M cell cycle checkpoint prior to the onset of apoptosis. J Biol Chem 2001;276:1127-1132.
17. Li Y, Wang X, Zhang X, Goodrich DW. Human hHpr1/p84/Thoc1 regulates transcriptional elongation and physically links RNA polymerase II and RNA processing factors. Mol Cell Biol 2005;25:4023-4033.
18. Guo S, Hakimi MA, Baillat D, Chen X, Farber MJ, Klein-Szanto AJ, et al. Linking transcriptional elongation and messenger RNA export to metastatic breast cancers. Cancer Res 2005;65:3011-3016.
19. Li Y, Lin AW, Zhang X, Wang Y, Wang X, Goodrich DW. Cancer cells and normal cells differ in their requirements for Thoc1. Cancer Res 2007;15:6657-6664.
20. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
21. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics In: Tumours of the Lung, Pleura, Thymus and Heart. WHO Classification of Tumours. IARC Press, Lyon, 2004; pp 9-68.
22. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
23. Tan D, Li Q, Deeb G, Ramnath N, Slocum HK, Brooks J, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003;34:597-604.
24. Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, et al. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol 2003;12:201-211.